Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
... patients with non-muscle invasive bladder cancer. OncoSec's core platform, ImmunoPulse, which is based on the intratumoral delivery of DNA IL-12, ...
Lycera Corp. is a biopharmaceutical company focused on the development of breakthrough drugs to address cancer and autoimmune diseases.
... processes that immunotherapy had to go through, it is now on the brink of becoming one of the standard procedures for cancer treatment, along with ...
... Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Malaysia.
Systemic Therapy of Metastatic Melanoma: On the Road to Cure
In this article, we summarize the systemic therapies now available for melanoma, with a focus on the recently approved agents for cutaneous melanoma; discuss important considerations in selecting a treatment from the available options; and highlight some of the promising investigational approaches for this disease.
In this article, we summarize the systemic therapies now available for melanoma, with a focus on the recently approved agents for cutaneous melanoma; discuss important considerations in selecting a treatment from the available options; and highlight some of the promising investigational approaches for this disease.
Commentaries
Have We Won the Race in the Treatment of Advanced Melanoma—Or Are We Just Learning to Walk?
The unprecedented improvements in melanoma therapeutics over a short period of time have been nothing short of extraordinary. It may be that we are now on a road to cure, but surely the destination is not yet in sight.
The unprecedented improvements in melanoma therapeutics over a short period of time have been nothing short of extraordinary. It may be that we are now on a road to cure, but surely the destination is not yet in sight.
Optimal Treatment Selection for Patients With Metastatic Melanoma
In early 2015, determining the optimal treatment regimen for a patient with metastatic melanoma remains challenging.
In early 2015, determining the optimal treatment regimen for a patient with metastatic melanoma remains challenging.
To Put That Into Context...
The Future of Systemic Therapy of Melanoma: Combinations, Predictive Biomarkers
While the last several decades saw a lack of progress in treatment outcomes in this setting, the outlook has recently changed dramatically, driven by a deepening understanding of melanoma biology and host immunology.
While the last several decades saw a lack of progress in treatment outcomes in this setting, the outlook has recently changed dramatically, driven by a deepening understanding of melanoma biology and host immunology.
OncoTherapy Network
For more information on targeted therapies and immunotherapies in skin cancer, check out our Skin Cancer/Melanoma Targets resource page--and join in on the conversation!
Science Daily Cancer News
Radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis, researchers have found. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease.
Tumors require blood to emerge and spread. That is why scientists believe that targeting blood vessel cells known as pericytes may offer a potential new therapeutic approach when combined with vascular growth factors responsible for cell death.
Many therapeutic cancer vaccines that are currently being developed are designed to direct the immune system against altered cancer-cell proteins. However, these vaccines can only be effective if the tumor cells present the altered protein to the immune system in a perfectly matching shape. Scientists have now described a test to predict whether this prerequisite for effective tumor vaccination is fulfilled.
Uterine sarcoma -- a potentially aggressive type of cancer that forms in tissues in the uterus -- was found in 0.22 % of women following a hysterectomy for benign conditions, a new large-scale study shows. Authors say findings may have implications for the risks associated with morcellation.
Single-letter genetic variations within parts of the genome once dismissed as 'junk DNA' can increase cancer risk through wormhole-like effects on far-off genes, new research shows. Researchers found that DNA sequences within 'gene deserts' -- so called because they are completely devoid of genes -- can regulate gene activity elsewhere by forming DNA loops across relatively large distances.
Scientists have developed a new HPV (human papilloma virus) vaccine which protects against nine types of the virus -- seven of which cause most cases of cervical cancer. The new vaccine offers significantly greater protection than the current vaccine, which protects against only two cancer causing types of HPV.
Public health researchers have analyzed soda consumption data in order to characterize people's exposure to a potentially carcinogenic byproduct of some types of caramel color. Caramel color is a common ingredient in colas and other dark soft drinks. The results show that between 44 and 58 percent of people over the age of six typically have at least one can of soda per day, possibly more, potentially exposing them to 4-methylimidazole (4-MEI), a possible human carcinogen formed during the manufacture of some kinds of caramel color.
Tambahkan Komentar